Menu Search
Equities

OraSure Technologies Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
EP3:BRN

OraSure Technologies Inc

Actions
  • Price (CHF)8.00
  • Today's Change0.00 / 0.00%
  • Shares traded1.50k
  • 1 Year change--
  • Beta0.9023
Data delayed at least 15 minutes, as of Jan 24 2022.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

OraSure Technologies, Inc. transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. The Company improves the access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers. Its products and services include OraQuick ADVANCE Rapid HIV1/2 Antibody Test, OraQuick HIV Self-Test, and Diagnostics Direct Syphilis Health Check.

  • Revenue in USD (TTM)125.70m
  • Net income in USD-60.24m
  • Incorporated2000
  • Employees501.00
  • Location
    OraSure Technologies Inc220 E First StBETHLEHEM 18015United StatesUSA
  • Phone+1 (503) 641-6115
  • Fax+1 (610) 882-1830
  • Websitehttps://www.orasure.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		OSUR:NSQ since
announced		Transaction
value
Biomedomics IncAnnounced05 Nov 202505 Nov 2025Announced5.45%4.00m
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.